

Delivering excellence in ophthalmic clinical trials



Cerulea
Clinical Trials
CENTRE FOR EYE RESEARCH AUSTRALIA

CERULEA
CAPABILITIES



Introduction

At Cerulea Clinical Trials, our work is driven by a simple but powerful belief for a world free of vision loss and blindness via faster access to cutting edge therapies and devices.

As CEO, I am incredibly proud of what Cerulea represents now and for the future. It exists as a place where innovation meets compassion, where science meets purpose. With an unwavering commitment, we help to accelerate discoveries, empower patients, and partner with organisations who, like us, believe that sight is worth fighting for.

As Australia's largest ophthalmic clinical trials centre, Cerulea brings more than 25 years of experience and a legacy of over 200 clinical trials across all phases of ocular conditions to deliver the most advanced therapies in the world and push the boundaries of what is possible in vision science.

What truly differentiates Cerulea is the heart behind the expertise. Uniquely positioned to reach patients across Victoria Cerulea is supported by a broad referral network, satellite sites, and strong partnerships with advocacy groups, allowing those seeking a therapy

help restore their independence, protect their future, or simply let them see the faces and things they love. We move with urgency utilising rapid ethics pathways, favourable regulatory processes, and the advantage of Australia's R&D tax incentives, thus offering local and global sponsors speed without compromise. Our teams specialise in fast, high quality study start up and have repeatedly proven our strength as a lead site for international programs.

On behalf of Cerulea, I would like to personally thank you for your trust, collaboration, and commitment to advancing better ocular outcomes. Together, by shaping the next generation of ocular therapies, we can bring tomorrow's treatments to patients today and provide hope for a clearer tomorrow.

Dr Michelle Bradney
CEO, CERULEA CLINICAL TRIALS

Our Vision

A world free from vision loss and blindness through faster access to breakthrough therapies.

Our Mission

To deliver world class, high-quality, patient-focused ophthalmic clinical trials that move research into real-world treatments.

Our Values



Unity



Agility



Integrity



**Making a
Difference**


Therapeutic Areas

Primarily focused on interventional trials delivered to a global commercial standard.


Expertise in several therapeutic areas and trial types:




Cell & Gene Therapy Trials




Medical Device Trials




**Diseases of The Retina
(AMD, GA, DME)**



Inherited and Rare Retinal Diseases



Glaucoma



Uveitis



Thyroid Eye Disease



World-Class Facilities & Capabilities

- + Australia's largest ophthalmic clinical trial site
- + Incorporates advanced technologies, multimodal imaging, bioprocessing, and efficiencies with our own PC2 lab & onsite pharmacy
- + Expertise across cell & gene therapy, biologics, and surgical medical devices
- + Integrated digital platforms that streamline data capture and quality
- + Data accepted by FDA, EMA and other regulators



Experienced & Trusted Partner

- + 25+ years of delivering 200+ ophthalmic Phase I – IV trials
- + Access to leading ophthalmologists, KOLs and specialist research teams
- + Scientific advisory, protocol design and early development guidance
- + In-house startup specialists and proven lead-site performance
- + We have the rare ability to conduct both front and back of eye trials - AMD, GA, DME, IRD, glaucoma, uveitis, TED, corneal disease & more
- + Cross specialty ophthalmic assessments for oncology, neurology, metabolism, immunology, vascular medicine & more



Patient Access & Recruitment Strength

- + Large referral network with satellite and decentralised hospital partners
- + Extensive recruitment databases and strong advocacy partnerships
- + Diverse and educated population



Operational Excellence, Speed & Cost Efficiency

- + Australia provides an unparalleled environment for conducting first in human and early phase clinical trials
- + Rapid ethics and regulatory efficiencies, often as short as 6-8 weeks
- + Substantial cost benefits and tax incentives - up to 60% less expensive than the US and EU, with tax incentive schemes of up to 43.5%





Dr Michelle Bradney
CEO

mbradney@cerulea.org.au



Prof Lyndell Lim
CHIEF MEDICAL OFFICER

llim@cerulea.org.au



Marios Constantinou
HEAD OF CLINICAL OPERATIONS

mconstaninou@cerulea.org.au



**Cerulea
Clinical Trials**
CENTRE FOR EYE RESEARCH AUSTRALIA

Level 7, 32 Gisborne Street,
East Melbourne, Victoria 3002 Australia
ceruleaclinicaltrials.org.au